皇冠体育app

British drugmaker GlaxoSmithKline has issued a statement on its website in response to 皇冠体育app's investigation on its bribery scandal.

The statement says the company is "deeply concerned and disappointed by these serious allegations of fraudulent behaviour and ethical misconduct by certain individuals at the company and third-party agencies." It also says "such behaviour would be a clear breach of 's systems, governance procedures, values and standards. GSK has zero tolerance for any behaviour of this nature."

The drugmaker is under investigation for offering bribery to Chinese government officials, medical associations, and doctors to boost sales and prices.

GSK emphasizes in the statement that it fully respects 皇冠体育app's laws and regulations, and will cooperate fully with the Chinese authorities in the investigation of these new allegations.

The British Foreign Office says it is now contacting GlaxoSmithKline's headquarters in the UK, and seeking more information from the Chinese side over 皇冠体育app's probe into the company's conduct.

皇冠体育app's Ministry of Public Security announced last week that several senior executives from GSK 皇冠体育app are being investigated for suspected bribery and tax-related violations.